For Healthcare Professionals

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

clipboard-pencil

About the study

The purpose of this study is to measure the safety and decrease in daytime sleepiness in subjects with Idiopathic Hypersomnia when taking ALKS 2680 tablets compared with placebo tablets
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Is willing and able, in the opinion of the Investigator, to understand and comply with protocol requirements, including: lifestyle considerations and restrictions, adherence to contraception guidance, adherence to actigraphy and diary requirements, if receiving treatment for OSA, adherence to primary OSA therapy over the 30 days prior to Visit 1, and throughout the study, including during overnight visits.
  2. Meets the diagnostic criteria of Idiopathic Hypersomnia according to ICSD-3-TR guidelines, confirmed by the diagnostic evaluations (PSG/MSLT/actigraphy) within the previous 10 years

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Has another comorbid sleep disorder or condition that may influence the sleep-wake cycle
  2. Has a history or presence at Visit 1 of other clinically significant (treated or untreated) illness, disease, abnormality, or surgical procedure that, in the opinion of the Investigator, might compromise subject safety, interfere with any study assessment, or affect the subject's ability to complete the study
  3. Is currently enrolled in another clinical study or used any investigational drug or device within 30 days prior to Visit 1
  4. Is currently pregnant, breastfeeding, or is planning to become pregnant during the study

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study Details


Contition

Idiopathic Hypersomnia

Age

18 - 70

Phase

PHASE2

Participants Needed

96

Est. Completion Date

Jun 30, 2026

Treatment Type

INTERVENTIONAL


Sponsor

Alkermes, Inc.

ClinicalTrials.gov NCT Identifier

NCT06843590

Study Number

ALKS 2680-203

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.